Literature DB >> 6135869

Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.

J Finne, M Leinonen, P H Mäkelä.   

Abstract

Glycopeptides containing polysialic acid units were isolated from human and rat brain and tested for reactivity with antibodies against meningococcal capsules. The polysialosyl glycopeptides bound specifically to horse antiserum against meningococcus group B. The interaction was inhibited by capsular polysaccharides from meningococcus group B but not groups A or C. The capsular polysaccharide of Escherichia coli K1, which is immunochemically similar to the group B polysaccharide, also inhibited binding. These findings could explain the failure to develop efficient vaccines against group B meningococcus or E coli K1 and also suggest that immunological tolerance could be a factor in the pathogenesis of meningitis caused by these bacteria. The presence of the cross-reactive brain component calls for caution in efforts to develop capsular polysaccharide vaccines from these bacteria or the proposed use of passively administered antibodies as immunotherapy of neonatal meningitis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6135869     DOI: 10.1016/s0140-6736(83)90340-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  264 in total

Review 1.  Clinical implications of the specialised B cell response to polysaccharide encapsulated pathogens.

Authors:  C G Vinuesa; C de Lucas; M C Cook
Journal:  Postgrad Med J       Date:  2001-09       Impact factor: 2.401

2.  Immunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci.

Authors:  K A Jolley; L Appleby; J C Wright; M Christodoulides; J E Heckels
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

3.  Development, characterization, and functional activity of a panel of specific monoclonal antibodies to inner core lipopolysaccharide epitopes in Neisseria meningitidis.

Authors:  Margaret Anne J Gidney; Joyce S Plested; Suzanne Lacelle; Philip A Coull; J Claire Wright; Katherine Makepeace; Jean-Robert Brisson; Andrew D Cox; E Richard Moxon; James C Richards
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

4.  Vaccination with attenuated Neisseria meningitidis strains protects against challenge with live Meningococci.

Authors:  Yanwen Li; Yao-hui Sun; Cathy Ison; Myron M Levine; Christoph M Tang
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

5.  Mutant bacteriophage with non-catalytic endosialidase binds to both bacterial and eukaryotic polysialic acid and can be used as probe for its detection.

Authors:  J Aalto; S Pelkonen; H Kalimo; J Finne
Journal:  Glycoconj J       Date:  2001-10       Impact factor: 2.916

6.  Distribution of surface protein variants among hyperinvasive meningococci: implications for vaccine design.

Authors:  Rachel Urwin; Joanne E Russell; Emily A L Thompson; Edward C Holmes; Ian M Feavers; Martin C J Maiden
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 7.  Bacterial outer membrane vesicles in disease and preventive medicine.

Authors:  Can M Unal; Viveka Schaar; Kristian Riesbeck
Journal:  Semin Immunopathol       Date:  2010-12-12       Impact factor: 9.623

8.  Effect of Tamm-Horsfall urinary glycoprotein on phagocytosis and killing of type I-fimbriated Escherichia coli.

Authors:  S M Kuriyama; F J Silverblatt
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

9.  Guillain-Barré syndrome and Campylobacter jejuni: a serological study.

Authors:  J Kaldor; B R Speed
Journal:  Br Med J (Clin Res Ed)       Date:  1984-06-23

Review 10.  The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.

Authors:  Gary W Zlotnick; Thomas R Jones; Paul Liberator; Li Hao; Shannon Harris; Lisa K McNeil; Duzhang Zhu; John Perez; Joseph Eiden; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.